Strategic Acquisition Chemaxon was acquired by Certara in 2024 to close gaps in the design-make-test-analyze cycle and speed up biosimulation and new medicine launches, presenting a potential cross-sell of Certara’s platform capabilities to Chemaxon’s existing base.

Expansion Opportunities Post-acquisition integration with Certara suggests opportunities to expand Chemaxon’s cheminformatics tools into Certara’s model-informed drug development workflows, offering upsell for end-to-end simulation and analytics.

Large User Base With over one million scientists and researchers using Chemaxon tools, there is a broad opportunity to expand enterprise-scale deployments, renewals, and premium support services across academic and industry segments.

Tech & Data Fit Chemaxon’s tech stack including Snowflake, Datadog, GitHub, and BI tools aligns well with data-heavy cheminformatics and biosimulation needs, enabling potential upsell of data analytics, monitoring, and cloud-based collaboration offerings.

Revenue Benchmark Current revenue is in the $10–25M range; targeting mid-market and enterprise customers with integrated lifecycle solutions through Certara could drive higher contract values and longer-term renewals.